(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/015628 A1

(51) **International Patent Classification**:
C07D 498/04 (2006.01) ***A61P 43/00*** (2006.01)
A61K 31/424 (2006.01)

(21) **International Application Number**:
PCT/EP2009/060094

(22) **International Filing Date**:
4 August 2009 (04.08.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

08161930.6	6 August 2008 (06.08.2008)	EP
09150553.7	14 January 2009 (14.01.2009)	EP
61/205,096	14 January 2009 (14.01.2009)	US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BRUCE, Ian** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **CULSHAW, Andrew James** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **DEVEREUX, Nicholas James** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **GESSIER, François** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **MCKENNA, Jeffrey** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **NEEF, James** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB). **OAKMAN, Helen Elizabeth** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex Sussex RH12 5AB (GB).

(74) **Agents**: **VOEGELI-LANGE, Regina** et al.; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/015628 A1

(54) **Title**: PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS



(I)

(57) **Abstract**: There are described pyrazolo [5.1 -b] oxazole derivatives of structure I useful as corticotropin releasing factor (CRF_1) receptor antagonists.